Another Trump drug price proposal bites the dust
A proposal to end rebates negotiated by PBMs was pulled back by the White House on Thursday. It’s the second drug price idea to be scrapped this week.
Regulatory
Judge: HHS overstepped bounds issuing list price disclosure rule
The rule requiring drugmakers to state the price of treatments in DTC ads was set to go into effect on Tuesday.
FDA clears the air around vape product marketing
The latest guidance on e-cigarettes is a culmination of the FDA’s and former commissioner Scott Gottlieb’s mission to regulate the industry.
Opioid marketing under the microscope in day two of Oklahoma trial
A doctor who had been paid speaking and consulting fees by opioid manufacturers testified on Wednesday.
Sooner than you think: Pharma scrambles for drug price ad deadline
The ruling is in. After months of speculation, the Trump administration will require pharma companies to include the list price of a drug in direct-to-consumer TV ads — and sooner than most experts believed.
What’s next for the post-Gottlieb FDA
With the Trump administration putting out fires elsewhere, it could be a long temporary tenure for Dr. Scott Gottlieb’s acting replacement.
Live blog: PBMs face congressional grilling
The latest from the Senate Finance Committee’s grilling of executives from Cigna, CVS Health and CVS Caremark, Humana and OptumRx
MM&M’s annotated guide to the most essential DTC regulations and requirements
MM&M presents its first annotated guide to the most essential DTC regulations and requirements.
Eli Lilly, Johnson & Johnson take initiative, get in front of PhRMA guidelines
Eli Lilly and Johnson & Johnson take the lead on PhRMA’s new guidelines for DTC ads.
Purdue Pharma reaches first opioid-related lawsuit settlement
Purdue is settling a lawsuit brought by Oklahoma for $270 million. It is facing more than 1,600 lawsuits nationwide.
Want to read more?
Please login or register first to view this content.
